California, August 27, 2025
News Summary
California-based Kite, under Gilead Sciences Inc., has reached a $350 million agreement to acquire Interius BioTherapeutics. This acquisition aims to enhance Kite’s in vivo CAR therapy development and integrate Interius’s innovative technology, which allows in-body generation of CAR T-cells. The merger will establish a center of excellence in Philadelphia and is expected to streamline treatment processes while potentially impacting Gilead’s earnings per share in 2025.
California – Kite, a California-based global biopharmaceutical company under Gilead Sciences Inc., has announced a definitive agreement to acquire Interius BioTherapeutics, a Philadelphia-based company, for $350 million. This acquisition will incorporate all of Interius’ outstanding share capital, payable at closing, and plans to enhance Kite’s development of in vivo CAR therapeutics.
Once the acquisition is finalized, Interius’s operational team and employees will be integrated into Kite’s research team. This merger aims to establish a center of excellence in Philadelphia dedicated to advancing next-generation in vivo therapies. The acquisition is anticipated to streamline treatment timelines and improve patient outcomes, reflecting a growing commitment to innovative cancer therapies.
Interius BioTherapeutics is known for its innovative platform that enables the generation of ex vivo chimeric antigen receptor (CAR) T-cells directly within a patient’s body. Instead of the traditional method that involves cell harvesting, engineering, and reinfusion, Interius’s unique approach introduces DNA into the patient’s genome, allowing for a more convenient delivery via a single intravenous infusion without the need for preconditioning chemotherapy.
The modular design of Interius’s platform allows for rapid adaptation in treating various disease states, thus increasing patient access to cell therapies, particularly for those with rapidly progressing diseases. The integration of Interius’s technology with Kite’s existing expertise is expected to enhance the development and administration of in vivo therapies significantly.
Financially, Kite’s acquisition is projected to affect Gilead’s GAAP and non-GAAP earnings per share (EPS) by approximately $0.23-$0.25 in 2025. The closing of the transaction hinges upon the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.
Kite has established itself as a leader in the field of cell therapy, treating more patients with CAR T-cell therapy than any other company to date. Gilead Sciences has a history of over three decades of medical breakthroughs and operates across more than 35 countries globally. Interius BioTherapeutics specializes in engineering targeted, programmable vectors tailored for the precise delivery of genetic medicines aimed at combating complex diseases.
Key Features of the Acquisition
| Feature | Details |
|---|---|
| Acquisition Cost | $350 million cash |
| Integration | Interius employees will integrate into Kite’s research team |
| Key Technology | In vivo platform for CAR T-cell generation within the body |
| Impact on EPS | Negative impact of approximately $0.23-$0.25 in 2025 |
| Advisors | TD Cowen for Kite, Evercore for Interius |
| Market Position | Kite is a leader in CAR T-cell therapy |
FAQs
What is the purpose of the acquisition?
The acquisition aims to enhance Kite’s capabilities in developing next-generation in vivo therapies, streamlining treatment processes and improving patient outcomes.
How does Interius’s therapy differ from traditional CAR T-cell therapies?
Interius’s therapy allows generation of CAR T-cells directly within the patient’s body, potentially delivered via a single intravenous infusion, unlike traditional methods requiring cell harvesting and engineering.
What is the expected financial impact of the acquisition?
The deal is expected to reduce Gilead’s GAAP and non-GAAP EPS by approximately $0.23-$0.25 in 2025.
Which companies are involved in this transaction?
Kite, a subsidiary of Gilead Sciences, is acquiring Interius BioTherapeutics.
Where will the center of excellence be located?
The center of excellence will be established in Philadelphia, Pennsylvania, focusing on in vivo therapies.
Deeper Dive: News & Info About This Topic
- Business Wire: Kite to Acquire Interius BioTherapeutics
- Wikipedia: CAR T-cell therapy
- Reuters: Gilead Unit to Acquire Interius
- Google Search: Interius BioTherapeutics
- AINVEST: Gilead Sciences Kite Acquire Interius
- Encyclopedia Britannica: Gene therapy
Author: STAFF HERE MISSION VIEJO WRITER
MISSION VIEJO STAFF WRITER The MISSION VIEJO STAFF WRITER represents the experienced team at HEREMissionViejo.com, your go-to source for actionable local news and information in Mission Viejo, Orange County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Oso Fit 5K Fun Run and Community Health Fair, Walk Against Drugs & Community Fair, and National Night Out. Our coverage extends to key organizations like the Mission Viejo Chamber of Commerce and Providence Mission Hospital Mission Viejo, plus leading businesses in retail and education that power the local economy such as The Shops at Mission Viejo, Capistrano Unified School District, and Amazon Delivery Station. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HERESanDiego.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.
